Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease-Reference-Cited by-同舟云学术

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

Published:2010-10 Issue:4 Volume:160 Page:655-661.e2
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

White Harvey,Held Claes,Stewart Ralph,Watson David,Harrington Robert,Budaj Andrzej,Steg Ph. Gabriel,Cannon Christopher P.,Krug-Gourley Susan,Wittes Janet,Trivedi Trupti,Tarka Elizabeth,Wallentin Lars

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies;Lancet,2010

2. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target;Zalewski;Arterioscler Thromb Vasc Biol,2005

3. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages;Carpenter;FEBS Lett,2001

4. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL;Hsieh;Atherosclerosis,2000

5. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor;Macphee;Biochem J,1999

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. La phospholipase A2 associée aux lipoprotéines (Lp-PLA2) : biomarqueur pertinent et cible thérapeutique ?;Annales Pharmaceutiques Françaises;2024-09

2. Associations between psychosocial burden and prognostic biomarkers in patients with chronic coronary syndrome: a STABILITY substudy;European Journal of Preventive Cardiology;2024-08-06

3. Sleep quality and its underrated role: Associations between sleep-related symptoms and cardiovascular biomarkers;International Journal of Cardiology;2024-01

4. Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome;International Journal of Cardiology;2024-01

5. Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21);PLOS ONE;2023-11-14